Corticosteroids for the common cold by Hayward, Gail et al.
Bond University
Research Repository
Corticosteroids for the common cold
Hayward, Gail; Thompson, Matthew J.; Perera, Rafael; Del Mar, Chris B.; Glasziou, Paul P.;
Heneghan, Carl J.
Published in:
Cochrane Database of Systematic Reviews
DOI:
10.1002/14651858.CD008116.pub3
Published: 13/10/2015
Document Version:
Publisher's PDF, also known as Version of record
Link to publication in Bond University research repository.
Recommended citation(APA):
Hayward, G., Thompson, M. J., Perera, R., Del Mar, C. B., Glasziou, P. P., & Heneghan, C. J. (2015).
Corticosteroids for the common cold. Cochrane Database of Systematic Reviews, 2015(3), [CD008116].
https://doi.org/10.1002/14651858.CD008116.pub3
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository
coordinator.
Download date: 06 Nov 2019
Cochrane Database of Systematic Reviews
Corticosteroids for the common cold (Review)
Hayward G, Thompson MJ, Perera R, Del Mar CB, Glasziou PP, Heneghan CJ
Hayward G, Thompson MJ, Perera R, Del Mar CB, Glasziou PP, Heneghan CJ.
Corticosteroids for the common cold.
Cochrane Database of Systematic Reviews 2015, Issue 10. Art. No.: CD008116.
DOI: 10.1002/14651858.CD008116.pub3.
www.cochranelibrary.com
Corticosteroids for the common cold (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8
10DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Rhinovirus infection, Outcome 1 Number of patients with rhinovirus-positive nasopharyngeal
aspirates at day 7 of treatment. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
20APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
24FEEDBACK . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
25SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
26DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
26INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iCorticosteroids for the common cold (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Corticosteroids for the common cold
Gail Hayward1 , Matthew J Thompson2 , Rafael Perera1, Chris B Del Mar3, Paul P Glasziou3, Carl J Heneghan1
1Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK. 2Department of Family Medicine,
University ofWashington, Seattle,WA, USA. 3Centre for Research in Evidence-Based Practice (CREBP), Bond University, Gold Coast,
Australia
Contact address: Gail Hayward, Nuffield Department of Primary Care Health Sciences, University of Oxford, New Radcliffe House,
Radcliffe Observatory Quarter, Oxford, Oxfordshire, OX2 6GG, UK. gail.hayward@phc.ox.ac.uk, ghayward1@googlemail.com.
Editorial group: Cochrane Acute Respiratory Infections Group.
Publication status and date: Edited (no change to conclusions), comment added to review, published in Issue 3, 2016.
Citation: Hayward G, Thompson MJ, Perera R, Del Mar CB, Glasziou PP, Heneghan CJ. Corticosteroids for the common cold.
Cochrane Database of Systematic Reviews 2015, Issue 10. Art. No.: CD008116. DOI: 10.1002/14651858.CD008116.pub3.
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
The common cold is a frequent illness, which, although benign and self limiting, results in many consultations to primary care and
considerable loss of school or work days. Current symptomatic treatments have limited benefit. Corticosteroids are an effective treatment
in other upper respiratory tract infections and their anti-inflammatory effects may also be beneficial in the common cold. This updated
review has included one additional study.
Objectives
To compare corticosteroids versus usual care for the common cold on measures of symptom resolution and improvement in children
and adults.
Search methods
We searchedCochraneCentral Register of ControlledTrials (CENTRAL2015, Issue 4), which includes the Acute Respiratory Infections
(ARI) Group’s Specialised Register, the Database of Reviews of Effects (DARE) (2015, Issue 2), NHS Health Economics Database
(2015, Issue 2), MEDLINE (1948 to May week 3, 2015) and EMBASE (January 2010 to May 2015).
Selection criteria
Randomised, double-blind, controlled trials comparing corticosteroids to placebo or to standard clinical management.
Data collection and analysis
Two review authors independently extracted data and assessed trial quality.We were unable to performmeta-analysis and instead present
a narrative description of the available evidence.
Main results
We included three trials (353 participants). Two trials compared intranasal corticosteroids to placebo and one trial compared intranasal
corticosteroids to usual care; no trials studied oral corticosteroids. In the two placebo-controlled trials, no benefit of intranasal corticos-
teroids was demonstrated for duration or severity of symptoms. The risk of bias overall was low or unclear in these two trials. In a trial
of 54 participants, the mean number of symptomatic days was 10.3 in the placebo group, compared to 10.7 in those using intranasal
corticosteroids (P value = 0.72). A second trial of 199 participants reported no significant differences in the duration of symptoms.
The single-blind trial in children aged two to 14 years, who were also receiving oral antibiotics, had inadequate reporting of outcome
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measures regarding symptom resolution. The overall risk of bias was high for this trial. Mean symptom severity scores were significantly
lower in the group receiving intranasal steroids in addition to oral amoxicillin. One placebo-controlled trial reported the presence of
rhinovirus in nasal aspirates and found no differences. Only one of the three trials reported on adverse events; no differences were
found. Two trials reported secondary bacterial infections (one case of sinusitis, one case of acute otitis media; both in the corticosteroid
groups). A lack of comparable outcome measures meant that we were unable to combine the data.
Authors’ conclusions
Current evidence does not support the use of intranasal corticosteroids for symptomatic relief from the common cold. However, there
were only three trials, one of which was very poor quality, and there was limited statistical power overall. Further large, randomised,
double-blind, placebo-controlled trials in adults and children are required to answer this question.
P L A I N L A N G U A G E S U M M A R Y
Steroids for the common cold
Review question
We reviewed the evidence for using steroid medications to improve symptoms in patients who have a common cold.
Background
Common colds are experienced by over half a billion patients annually in the USA alone and result in significant loss of productivity.
Although there are a number of medications used to help improve the symptoms of the common cold, none have good evidence of
benefit. Steroids (corticosteroids) have been shown to help relieve symptoms in other types of upper respiratory tract infections by
reducing the inflammation of the lining of the nose and throat, which means they might also improve the symptoms of the common
cold.
Study characteristics
Our evidence is current to May 2015. We found three trials in total. Two trials recruited adults from the general population or from
among hospital staff in Finland. These trials (total 253 adults) compared intranasal steroid sprays, which allow steroids to be puffed
into the nostrils, to sprays containing placebo only. We found a third trial, which recruited 100 children referred to outpatient clinics
in an Iranian paediatric hospital. This trial compared intranasal steroid spray to no spray and gave oral antibiotics to all participants.
Key results and quality of the evidence
Neither of the two trials comparing steroid spray to placebo spray in adults showed a benefit of steroids across a range of different
measures. The trial comparing steroid spray to no spray in children did find some evidence of benefit but we rated the quality of the
evidence from this trial as very poor and the results were unclear. We could not combine the results of the trials to assess this question
further. There were no reports of adverse events.
Conclusion
The available evidence suggests that we should not use intranasal steroids for the common cold. However, as we found only three small
trials, we cannot be sure that there is no effect without performing larger, well-designed trials.
B A C K G R O U N D
Description of the condition
The common cold is the conventional term for upper respiratory
tract viral infections that are benign and self limiting. Over 500
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million patients develop colds in a year in the United States (
Fendrick 2003), resulting in 22 million school days lost (Adams
1999), and an annual lost productivity of almost USD 25 billion
(Bramley 2002).
The typical symptoms of a cold include nasal obstruction, rhinor-
rhoea, sneezing, sore throat and, on occasion, mild fever, headache
and myalgia. The most common causative agent is the rhinovirus
(Makela 1998), although several different viral families have been
implicated and bacterial infection can give rise to the same symp-
toms (Kaiser 1996). Rhinoviral infection begins with deposition
of virus on the nasal epithelium via airborne droplets or by hand
from fomites (any inanimate object, e.g. kitchen sink, that can
carry disease-causing organisms). The inflammatory response of
nasal mucosa to the viral infection involves vasodilation and in-
creased vascular permeability, leading to the symptoms of sneez-
ing, nasal congestion and rhinorrhoea.
Description of the intervention
Management options for common colds currently focus on symp-
tom alleviation and include decongestants, where evidence has not
recently been assessed, and antihistamines, for which there is no
evidence of benefit (Wiest 2011). Whilst both of these therapies
target the effects of the inflammatory response of the nasal mucosa
to the virus, this inflammatory response could also be modulated
by the use of corticosteroids, which inhibit the generation of pro-
inflammatory cytokines in nasal epithelium (Mygind 2001).
How the intervention might work
Corticosteroids have been demonstrated to increase the likelihood
of resolution or improvement of symptoms in acute sinusitis (
Zalmanovici 2013), as well as in viral croup (Russell 2011), and
sore throats (Hayward 2009). Their anti-inflammatory actions on
the nasal mucosa may also reduce the symptoms and duration of
the common cold.
Why it is important to do this review
The common cold results in significant morbidity and loss of
productivity. Current treatment options have limited evidence of
benefit. Corticosteroids may offer more effective symptom relief,
given their actions in other infections of the upper respiratory
tract, and it is important to examine the evidence for this. No
previous systematic reviews have addressed this question.
O B J E C T I V E S
To compare corticosteroids versus usual care for the common cold
on measures of symptom resolution and improvement in children
and adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) comparing corticosteroids
to placebo or to standard clinical management (for example, con-
servative measures such as pain relief ) for the common cold.
Types of participants
Children and adults with the common cold, defined by clinical di-
agnosis. We excluded trials where a definitive diagnosis of another
upper respiratory condition was present (for example, influenza
or sinusitis). We also excluded trials where the common cold was
experimentally induced if the intervention was initiated before the
cold was induced. We did not impose any age limits.
Types of interventions
Oral or inhaled corticosteroids versus standard clinical care or
placebo in the control group. We included trials reporting com-
bined interventions if they allowed a direct comparison between
corticosteroids and usual care for the common cold and were un-
confounded. By unconfounded, we mean studies where the two
groups were not treated differently, except for the provision of
steroids to one group. Confounding can occur by the use of a
different medication regime (for example, analgesics) for one of
the two groups. We excluded them if the two groups were treated
unequally apart from the corticosteroids.
Types of outcome measures
Primary outcomes
1. Proportion of participants with resolution or improvement
of symptoms (individual and global) within one month.
2. Time lapse before resolution of symptoms.
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Secondary outcomes
1. Adverse events necessitating discontinuation of treatment.
2. Relapse rates.
3. Microbiological consequences, for example, length of
shedding of virus from nasopharyngeal secretions, bacterial
culture from secretions.
4. Treatment for secondary infections.
5. Quality of life measures and economic costs.
Search methods for identification of studies
Electronic searches
For this 2015 update we searched theCochraneCentral Register of
Controlled Trials (CENTRAL 2015, Issue 4), which includes the
Acute Respiratory Infections (ARI) Group’s Specialised Register,
MEDLINE (May 2012 toMayweek 3, 2015) andEMBASE (May
2012 to May 2015). We also searched the Database of Reviews
of Effects (DARE) (2015, Issue 2 of 4) and the NHS Health
Economics Database (NHS EED) (2015, Issue 2 of 4) from The
Cochrane Library.
Previously we searched CENTRAL (2012, Issue 5), the Database
of Reviews of Effects (DARE) and the NHS Health Economics
Database (searched 22 May 2012), MEDLINE (1948 to May
week 2, 2012) and EMBASE (January 2010 to May 2012). We
combined the MEDLINE search with the Cochrane Highly Sen-
sitive Search Strategy for identifying randomised trials in MED-
LINE: sensitivity- and precision-maximising version, Ovid format
(Lefebvre 2011). See Appendix 1 for the MEDLINE and CEN-
TRAL search strategy and Appendix 2 for the EMBASE search
strategy.
Searching other resources
We searched the World Health Organization (WHO) Interna-
tional Clinical Trials Registry Platform (ICTRP) and ClinicalTri-
als.gov trials registries (latest search 19 May 2014). We searched
the reference lists of all studies identified as relevant to increase the
yield of relevant study references.
Data collection and analysis
Selection of studies
Two review authors (GH, CDM) independently reviewed the ti-
tles and abstracts of the electronic search results to select relevant
articles. One review author (GH) obtained the full text of these
articles. Two review authors (GH, CDM) independently reviewed
full-text articles for their inclusion in the review. A third review
author (CH) resolved any disagreements by discussion. The review
authors were not blinded to the journal of origin, the authors, the
institutions or the magnitude of results.
Data extraction and management
Two review authors (GH, MT, CDM) independently extracted
data from included trials, entering data into an extraction template
and checking agreement. A third review author (CH) assisted with
resolving any disagreements. A statistician (RP) independently re-
viewed all data extracted from original publications to verify the
quality of methods and analysis used.We wrote to the trial authors
for clarification of data where information was lacking.
Assessment of risk of bias in included studies
Two review authors (GH, MT) independently assessed the
methodological quality of the included studies, with disagreements
documented and resolved by discussion with a third review au-
thor (CH). The specific aspects of methodological quality assessed
included random sequence generation (selection bias), allocation
concealment (selection bias), blinding (performance bias and de-
tection bias), incomplete outcome data (attrition bias), selective
reporting (reporting bias), treatment adherence, percentage par-
ticipation and comparability of groups on baseline characteristics.
We used theCochrane ’Risk of bias’ tool to perform the assessment
(Higgins 2011).
Measures of treatment effect
Symptom severity was reported as a mean symptom score in two
trials (Qvarnberg 2001; Rahmati 2013). In neither trial was it clear
how this was calculated. Duration of symptoms was reported as
mean duration of symptoms in days in two trials. We were unable
to combine data from individual trials. The number of patients
who were rhinovirus-positive at day seven is reported as a risk ratio
(Puhakka 1998).
Unit of analysis issues
We did not encounter unit of analysis issues.
Dealing with missing data
Completion rates were very high for all of our included trials and
so strategies for dealing with missing data were not required.
Assessment of heterogeneity
We did not assess heterogeneity.
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Assessment of reporting biases
The small number of studies meant that the use of funnel plots
was inappropriate. We attempted to contact trial authors to ask
for unpublished results.
Data synthesis
As our data were not amenable to meta-analysis, we addressed our
primary outcomes using a narrative description of the available
evidence.
Subgroup analysis and investigation of heterogeneity
We were unable to perform any subgroup analyses.
Sensitivity analysis
We were unable to perform sensitivity analysis.
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies tables.
Results of the search
The initial search of the electronic databases retrieved 2947 records
with duplicates removed.MEDLINE yielded 1492 records, CEN-
TRAL 1577 and EMBASE 1211. We also searched HEED and
DARE and these yielded 18 and 13 records, respectively. Of these
records we identified 10 studies that were potentially eligible based
on title and abstract. We obtained full-text copies of all 10 arti-
cles. From these 10 we included two studies and excluded eight.
In the updated search on 19 May 2015, MEDLINE yielded 166
records, EMBASE 1084, CENTRAL 504, NHS EED 10, HEED
0 and DARE 13 records. Once duplicates were removed the total
number of new records was 1216 of which we identified four as
potentially eligible based on title and abstract. We obtained full-
text copies and included one additional study (see Figure 1 for the
PRISMA flow chart).
5Corticosteroids for the common cold (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. PRISMA flow chart.
6Corticosteroids for the common cold (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Included studies
Twoof our included studies involved 199 and 54 adult participants
respectively, suffering from naturally developed colds (Puhakka
1998; Qvarnberg 2001). Both studies were performed in Finland
and recruited from the general population (Puhakka 1998), or hos-
pital staff (Qvarnberg 2001), and the majority were female (190/
254). Participants received intranasal fluticasone propionate 200
µg four times daily (Puhakka 1998), or beclomethasone dipropi-
onate 400 µg once daily (Qvarnberg 2001), for six or 14 days,
respectively. The third included study involved 100 children aged
two to 14 years attending the paediatric hospital in Bandar Abbas,
Iran (Rahmati 2013). Participants received either amoxicillin 80
to 100mg/kg alone for 14 days or amoxicillin and fluticasone nasal
spray, one puff twice a day, for 14 days. This study aimed to re-
cruit children with acute sinusitis. However, the eligibility criteria
included children with symptoms of common cold for less than
10 days with purulent nasal discharge and three days of fever over
39 degrees celsius; criteria compatible with a diagnosis of common
cold.
Excluded studies
We excluded 11 studies. Three studies involved experimentally
induced rhinovirus infection and, in each case, the steroid inter-
vention was started before inoculation of rhinovirus (Farr 1990;
Gustafson 1996; Proud 1994). Two studies did not offer an un-
confounded comparison between steroid and placebo, as their
nasal sprays contained antibiotics or mucolytic/vasoconstrictor
drugs, which were not also given to the placebo group (Peynegre
2005; Reinert 1991). One study used the same trial population as
Puhakka et al to examine salivary constituents and reported no rel-
evant outcome measures (Lenander-Lumikari 1999). One study
was a review focusing on seasonal and perennial rhinitis (Mygind
1977), and another excluded infection from its definition of non-
allergic rhinitis (Baccioglu Kavut 2013). Two studies assessed a
population who presented with rhinosinusitis symptoms for more
than 10 days, which we judged to be beyond the natural history
of duration of the common cold (Keith 2012; Tugrul 2014), and
the final study included children with chronic nasal obstruction
(Bellodi 2006).
Risk of bias in included studies
Two of the studies were double-blind trials comparing intranasal
corticosteroid to placebo (Puhakka 1998; Qvarnberg 2001). The
method of randomisation was not clearly reported in either study.
We were unsuccessful in our attempt to elicit more information
to support our assessment of risk of bias directly from the trial
authors.
The third study was a single-blind trial comparing intranasal cor-
ticosteroid and oral amoxicillin to amoxicillin alone (Rahmati
2013). We elicited further information directly from the authors
and found that this study had a high risk of performance, selection
and reporting bias.
The overall risk of bias is presented graphically in Figure 2 and
summarised in Figure 3. See Characteristics of included studies
for further details of our risk of bias assessment.
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Two studies used placebo intranasal sprays with identical con-
stituents to the intervention spray apart from the active corticos-
teroid (Puhakka 1998; Qvarnberg 2001). Qvarnberg 2001 used
the ’Easyhaler’ multidose powder inhaler designed for nasal appli-
cation for both placebo and steroid. Puhakka 1998 did not directly
describe the medication packaging used, although they do report
that they received both placebo and corticosteroid sprays from the
same pharmaceutical company.
Rahmati 2013 did not use a placebo comparison and therefore
had no allocation concealment.
Blinding
Two studies were described as double-blind (Puhakka 1998;
Qvarnberg 2001). No further details regarding this were reported,
although Qvarnberg 2001 reported that the randomisation code
was only broken after data entry was complete. Rahmati 2013
stated that outcome assessors were blinded, yet a number of out-
come measures required patient self report and patients were not
blinded as no placebo was used.
Incomplete outcome data
Completion rates were high in all studies with only 3/353 partic-
ipants failing to complete; two participants received placebo and
one corticosteroid.
Selective reporting
In two studies, reporting of data was incomplete. Puhakka 1998
stated that data on usage of the trial medications were collected
but they did not report these data; if participants in the steroid
group had poor compliance with the trial this could reduce the
likelihood of any positive effect. Rahmati 2013 displayed inade-
quate reporting of outcome measures in terms of both the time
points of the assessment and the way in which the measures were
assessed and calculated.
Other potential sources of bias
Puhakka 1998 reported that the placebo group as a whole con-
sumed a greater quantity of paracetamol tablets than the steroid
group (170 tablets compared to 141). This difference could in-
fluence the reporting of symptoms. The Puhakka 1998 trial was
supported by GlaxoWellcome Ltd and one trial author was em-
ployed by GlaxoWellcome Ltd. This company also manufactured
the steroid nasal spray used in the trial. No declarations of con-
flict of interest were made by the trial authors. The study drug for
Qvarnberg 2001 was provided by Orion Pharma, and one of the
trial authors worked for the company. No declarations of conflict
of interest were made by the trial authors.
Rahmati 2013 stated that if no improvement was seen in fever,
nasal congestion or cough, or if exacerbation of disease was evi-
dent, patients were reassessed and the antibiotics were changed if
necessary. Following direct communication with the authors they
stated that “As a whole, patients were assessed again and the an-
tibiotics were changed if necessary at any time. In fact, most of
the patients had received a different treatment, if they did not re-
spond to the first line antibiotic therapy after 3 days of the initial
treatment.” The type and duration of antibiotics once changed is
not reported and may have introduced performance bias.
Effects of interventions
The data extracted from the studies did not provide comparable
outcome measures and we were unable to obtain further compa-
rable data directly from the trial authors. Therefore, we have de-
scribed the results of each trial according to our stated outcome
measures.
Primary outcomes
1. Proportion of participants with resolution or
improvement of symptoms (individual and global) within
one month
Neither Puhakka 1998 norQvarnberg 2001 reported this outcome
at any time point.
The outcomes of complete and relative resolution were reported
as assessed by Rahmati 2013. However, despite direct communi-
cation with the authors, we were unable to establish the time point
at which these outcomes were assessed or the criteria upon which
they were based and therefore we do not feel the evidence is of
sufficient quality to be included.
Rahmati 2013 reported a mean ’severity of symptoms’ score. It
was unclear how this was calculated in relation to the individual
symptom scores they report. They state that the score refers to
the end of treatment - i.e. 14 days. They found that the score in
those children receiving intranasal corticosteroid and amoxicillin
reduced from 22.46 ± 2.61 to 11.68 ± 2.66. In those children just
receiving amoxicillin the mean score reduced from 23.5 ± 3.19
to 14.84 ± 2.92. The final scores were significantly lower in the
group receiving intranasal steroids. Qvarnberg 2001 reported that
the sum of symptom severity scores over two weeks was similar in
the two groups: 57.3 (maximum score 392) in the steroid group
versus 51.6 in the placebo group (P value = 0.48). No clinically
or statistically significant differences were shown in the summed
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severity (over two weeks follow-up) of the seven individual symp-
tom measures.
Rahmati 2013 also reported the percentage of patients scoring
zero to five for individual symptoms (zero for not affected, one for
very little problem, two for mild problem, three for moderately
bad, four for bad and five for severe). We were unable to clarify
the time point at which these scores were assessed. The paper
includes a table, which suggests that scores are significantly lower
for congestion, anterior discharge, posterior discharge, fullness,
headache, cough and malodour, but that scores on exhaustion,
fever and toothache were not significantly different. It is unclear
how this statistical significance was calculated.
2. Time lapse before resolution of symptoms
Puhakka 1998 reported that the duration of the common cold
symptoms of rhinorrhoea, nasal congestion and cough was equal
in both groups (illustrated in figures in the original article). Mean
duration of throat soreness was greater in the corticosteroid group
than the placebo group: 5.3 days versus 3.7 days (P value < 0.001).
Qvarnberg 2001 reported the mean number of symptomatic days
as 10.3 in the placebo group, compared to 10.7 in the corticos-
teroid group (P value = 0.72). Median time to recovery was 12
days in the steroid group and 11 days in the placebo group (log
rank test P value = 0.81).
Rahmati 2013 did not report this outcome.
Secondary outcomes
1. Adverse events necessitating discontinuation of treatment
Only one study reported adverse events (Puhakka 1998). There
were no adverse events necessitating discontinuation of treatment
in either group.
2. Relapse rates
Puhakka 1998 reported that no participants had symptoms requir-
ing additional follow-up from 21 days after the start of the trial,
suggesting a relapse rate of zero. Relapse rates were not assessed by
Qvarnberg 2001 or Rahmati 2013.
3. Microbiological consequences
Puhakka 1998 was the only trial to assess the presence of rhinovirus
by culture andpolymerase chain reaction (PCR) of nasopharyngeal
aspirates taken on day one and day seven (i.e. at the end of the
course of treatment). Therewere nodifferences in the percentage of
rhinovirus-positive participants at baseline.When assessed by viral
culture alone, there were significantly more rhinovirus-positive
participants at day seven in the corticosteroid group compared to
the placebo group (36% versus 14%, P value < 0.001) (Analysis
1.1).However, when the total number of positive samples fromday
seven detected by PCR and culture were combined there were no
significant differences between corticosteroid and placebo groups.
Viral culture may offer a more accurate representation of presence
of viable virus.
In an intention-to-treat-infected (ITTI) population analysis of
only those participants who were rhinovirus-positive on day one,
Puhakka 1998 reported no differences in the overall frequency of
symptoms between steroid and placebo groups. The mean dura-
tion of cough was shorter (8.0 versus 10.8 days, P value < 0.05)
and the severity of cough was lower on days three, four, seven,
eight and nine in the corticosteroid group. Nasal congestion was
less severe in the placebo group on days two and five.
No significant differences were seen between treatment groups
in the number of positive bacterial cultures from nasopharyngeal
aspirates. The effect on viral shedding was not assessed by any of
our included studies.
4. Treatment for secondary infections
Puhakka 1998 reported that one out of 100 participants receiving
corticosteroids and 0 out of 99 of participants receiving placebo
required antibiotics for acute otitis media. Qvarnberg 2001 re-
ported that one out of 28 participants in the corticosteroid group
and 0 out of 26 in the placebo group developed maxillary sinusitis
based on ultrasound. Rahmati 2013 treated all participants with
antibiotics and offered a second course of alternative antibiotics
if the child failed to improve after three days but did not supply
data on the number of children for whom this was the case.
5. Quality of life measures and economic costs
No data were reported in relation to quality of life measures,
economic costs or adverse events necessitating discontinuation of
treatment.
Puhakka 1998 reported that the steroid group had no clinical
changes and no symptoms classifiable as adverse events. Nasal ir-
ritation and bleeding did not occur significantly more often in
the steroid group than the placebo group. Qvarnberg 2001 and
Rahmati 2013 did not record or report upon adverse events.
D I S C U S S I O N
Summary of main results
This systematic review offers no evidence for benefit of intranasal
corticosteroids for the common cold. Themean time to resolution
of symptoms of the common cold was not significantly different
in those participants using intranasal steroids compared to placebo
in two of the studies included in this review. The symptom of sore
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throat had a longer duration in the corticosteroid group than the
placebo group in one trial (Puhakka 1998), but this difference was
not seen in the other trial (Qvarnberg 2001). The only trial to assess
complete resolution of symptoms, Rahmati 2013, was of very poor
quality and the outcome reporting was insufficient to allow us to
report these data. Although they did demonstrate a significantly
greater reduction inmean symptom severity score, this result must
be interpreted in the context of a methodologically flawed trial
performed in a population of patients that also included children
with acute sinusitis.
In those participants shown to be rhinovirus-positive, duration of
cough was shorter in the group receiving intranasal corticosteroids
but there was no difference when all participants were assessed; no
differences were seen in the trial by Qvarnberg 2001. The use of
corticosteroids did not result in any adverse consequences in terms
of bacteriological growth and did not result in significantly greater
requirement for secondary antibiotic therapy.However, there were
too few events in the combined studies to reliably detect a potential
difference.
A significantly higher percentage of participants in the corticos-
teroid group were found to be rhinovirus-positive by viral culture
in one trial (Puhakka 1998). This may imply that intranasal cor-
ticosteroids prolonged the duration of viable virus, which is of
interest in the context of the known immunosuppressant actions
of corticosteroids. However, prolonged presence of virus did not
correlate with prolonged duration of symptoms.
Overall completeness and applicability of
evidence
Only three trials of intranasal corticosteroids met the inclusion
criteria for this review. One of these was a pilot study including
only 54 participants (Qvarnberg 2001), and one was of very poor
quality, with inadequate reporting of outcome measures (Rahmati
2013). This limits the conclusions that can be drawn. The data
have limited applicability to older adults and there may be cul-
tural differences that influence the predominantly self reported
data from Finnish and Iranian patient groups. It is, of course, pos-
sible that a spray with inactive ingredients in itself is beneficial for
the common cold. However, a recent systematic review found no
convincing evidence of benefit of saline nasal spray for symptoms
of upper respiratory tract infections (King 2015).
Quality of the evidence
The two double-blind trials included in this review failed to de-
scribe in detail the procedures followed for randomisation and
blinding (Puhakka 1998; Qvarnberg 2001). However, both trials
reported almost complete outcome data, were at low risk of re-
porting bias and described procedures for allocation concealment.
Although no conflict of interest was reported, another potential
source of bias may have been the sponsorship of one of the trials
by the pharmaceutical company manufacturing the steroid spray
and the inclusion of one of its employees on the authorship of
the paper. The single-blind trial retrieved from our update of this
review was at high risk of selection, performance and reporting
bias, and results were not clearly presented (Rahmati 2013).
Potential biases in the review process
No potential biases are expected in this review process.
Agreements and disagreements with other
studies or reviews
We excluded two trials that evaluated the clinical effectiveness of
corticosteroids commenced in advance of inoculation with rhi-
novirus. Although the results of these studies have very limited
applicability to clinical practice, the results are interesting in the
context of the findings of our review. There were two trials involv-
ing 91 participants, of whom 75 became infected by rhinovirus.
In Farr 1990, the active treatment group of 19 participants re-
ceived a 10-day course of intranasal steroid beginning four days
before inoculation and a three-day course of twice daily 30 mg
prednisolone beginning one day before inoculation. A significantly
lower proportion of the corticosteroid group met the criteria for a
cold and also believed that they had a cold. The reported severity
of the cold was also lower on days one, two and five after inocu-
lation. However, there was no difference in individual symptom
score totals and summed symptom scores between corticosteroid
and placebo groups, nor in total mean mucus weights and tissue
use.
Gustafson 1996 examined the effect of 20 mg prednisolone three
times daily starting 11 hours before inoculation for five days in an
active treatment group of 21 participants. In contrast to Farr 1990,
they found no difference in the number of participants who met
the criteria for a cold. There were no differences in total symptom
scores, mucus production and tissue use between corticosteroid
and placebo groups. They reported increased mean viral titres in
the corticosteroid group but no difference in the frequency or
duration of viral shedding. In summary, trials using inoculation of
rhinovirus do not provide any consistent evidence of symptomatic
benefit of corticosteroids in the common cold.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is no evidence at present for benefit of intranasal corticos-
teroids for the common cold in adults, and the evidence for ben-
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efit in children is too low in quality to offer any useful additional
information.
The included trials did not show any evidence of adverse effects
of corticosteroid use. This suggests that patients using intranasal
corticosteroids for other conditions need not discontinue them
during a cold, although the effect on viral shedding and hence
spreading to contacts is not known.
Implications for research
We found only three small trials addressing the effect of intranasal
steroids for the common cold. A post-study sample size calcula-
tion based on the observed effect in one of the trials, Qvarnberg
2001, suggests a minimum of 330 participants would be required,
while the largest of the trials reported here had fewer than 200
participants. Based on this, further research is required to provide
a clear answer to this clinical question, ideally large double-blind,
placebo-controlled trials in both adult and paediatric populations,
assessing clearly defined and replicable outcomes including dura-
tion of symptoms, days off school or work, and the impact upon
shedding of active virus.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Puhakka 1998
Methods Double-blind, randomised, placebo-controlled trial
Participants 200 “young adults” (59 males of mean age 24.0 years ± 2.7 and 141 females of mean
age 24.1 years ± 3.6) with watery or purulent rhinitis and at least 1 of: cough, headache,
hoarseness, myalgia, nasal congestion, oral temperature higher than 37.0°C or throat
soreness were recruited. A total of 199 participants completed the study. Participants were
recruited from the general population in Finland through advertisements and contact
persons. Participants had to be healthy and without antibiotics for 4 weeks preceding
entry into the study. Exclusion criteria - allergic rhinitis, history of chronic or recurrent
sinusitis or lower respiratory tract disease, major nasal septal deviation, nasal polyposis,
pregnancy, lactation
Interventions Fluticasone propionate nasal spray daily dose 800 µg (administered as 2 puffs of 50 µg
to each nostril 4 times a day at equal intervals during waking hours). Administration
began 24 to 48 hours after onset of symptoms and continued for 6 days. Placebo spray
was identical to the study drug without fluticasone propionate
Outcomes Symptom severity scores via diary card - twice daily from days 1 to 6 then in the evening
from days 7 to 20, assessing the severity of the symptoms of watery rhinitis, purulent
rhinitis, nasal congestion, nasal irritation, nasal bleeding, blood in nasal mucous, cough,
sputum, headache, fever, throat soreness, hoarseness, sweating, myalgia, lethargy. Oral
temperature record on days 1 to 6 and then if participant felt feverish. Absence from
study or work. Consumption of paracetamol tablets. Nasopharyngeal aspirate on days 1
and 7 for rhinovirus culture, rhinovirus PCR and bacterial culture
Notes Paracetamol was permitted in participants with fever or pain. However, drugs affecting
nasal or lung function (including over-the-counter medications) were not allowed during
the study
Study drug and placebo were supplied by Glaxo Research and development
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The method of randomisation is not de-
scribed
Allocation concealment (selection bias) Low risk Study drug and placebo contained identical
ingredients with the exception of fluticas-
one propionate. Steroid and placebo sup-
plied by pharmaceutical company. Authors
do not explicitly comment on the nature of
the packaging
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Puhakka 1998 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Authors state that the study was double-
blind but do not give further detail regard-
ing this
Incomplete outcome data (attrition bias)
All outcomes
Low risk Only 1 patient (0.5%) from the placebo
group did not complete the study. They
were excluded for improper use of study
medication
Selective reporting (reporting bias) Low risk Reasonable reporting of outcomes, al-
though oftendatawere described in the text
rather than presented and standard devia-
tions were not mentioned. The use of study
medication (i.e. compliance with study)
was assessed but not reported
Other bias High risk Paracetamol use was recorded but not con-
trolled: 141 tablets were used in the cor-
ticosteroid group and 170 in the placebo
group. This difference may have affected
symptom scores
Comparability of groups on different prog-
nostic characteristics
Low risk Reports “no differences in demographic
characteristics”
Qvarnberg 2001
Methods Randomised, placebo-controlled, double-bind, parallel-group design
Participants 54 patients (49 women, 5 men) over 18 years of age with symptoms of acute common
cold having lasted from1 to 3 days. Recruited fromhospital staff in central Finland.Mean
age 40.3, range 23 to 57 years. Exclusion criteria: chronic systemic diseases, ongoing
treatment with corticosteroids, pregnancy
Interventions Beclomethasone dipropionate + lactose nasal spray 400 µg daily dose - 2 puffs of 100 µg
to each nostril once daily. Placebo spray lactose alone
Outcomes Symptom diaries - recording severity of nasal blockage, rhinorrhoea, nasal itching, sneez-
ing, cough, sore throat, hoarseness. Also, sum of symptom scores recorded. Rhinoscopic
and ultrasonographic (of the maxillary sinuses) findings at days 1, 7 and 14
Notes Orion Corporation Ltd supplied the study drugs
Risk of bias
Bias Authors’ judgement Support for judgement
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Qvarnberg 2001 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomisation code used - no further de-
tails supplied
Allocation concealment (selection bias) Low risk Same inhaler used for both placebo and
BDP administration. Non-active ingredi-
ents the same
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Double-blind design stated.Data entry was
blindedbut no further details regarding this
reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2/54 patients discontinued the study, 1
from each group
Selective reporting (reporting bias) Low risk All outcomes measured were reported in
either text or data
Other bias Unclear risk A high percentage of patients had been
treated for maxillary sinusitis previously:
19/26 in placebo and 14/28 in corticos-
teroid groups
Comparability of groups on different prog-
nostic characteristics
Low risk No statistically significant differences be-
tween groups at baseline on important
prognostic characteristics, e.g. duration of
cold symptoms before entry, symptom pro-
file, rhinoscopy and ultrasonography ap-
pearances, patient characteristics. No base-
line data were presented to support this
Rahmati 2013
Methods Single-blind, randomised trial comparing intranasal steroids and oral amoxicillin to oral
amoxicillin alone
Participants 100 children aged 2 to 14 with common colds lasting more than 10 days with nasal
or postnasal discharge or common cold lasting less than 10 days with purulent nasal
discharge and 3 to 4 days of rectally recorded fever greater than 39 °C. Exclusion criteria:
allergic rhinitis, nasal obstruction due to deviated nasal septum, nasal polyps, lack of
parental co-operation, contraindications to use of the intervention medication, wound
or lesion in the nasal mucosa. Children were recruited from outpatient clinics at the
paediatric hospital in Iran
Interventions 50 µg of fluticasone propionate nasal spray (50 µg/puff, Flixonase, GSK) twice daily for
14 days Unclear which nostril was used
Both groups received amoxicillin 80 to 100 mg/kg/day
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Rahmati 2013 (Continued)
Outcomes Severity of symptoms as documented by blinded healthcare workers by phone or face to
face discussion on day 4 of the intervention and on days 10 to 14
Severity of symptoms was calculated for each symptom as 0 for not affected, 1 for very
little problem, 2 for mild problem, 3 for moderately bad, 4 for bad and 5 for severe
Total (mean) symptom severity score reported, however the authors do not describe
how this is calculated. They also do not state how many days post-intervention the
individual symptom scores were reported - this could be anywhere from 4 to 14 days
after recruitment
Complete recovery of symptoms - based, according to personal communication with
authors, on clinical assessment and patient self report, however, unclear method of cal-
culation and time point of assessment
Relative recovery of symptoms - the authors state in direct communication that this
was defined as recovery of associated symptoms such as cough, headache, malaise, facial
pain, irritability but it remains unclear how this was calculated and the time point of
assessment
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Communication with the authors: com-
puter-generated randomisation used
Allocation concealment (selection bias) High risk No control nasal spray used
Blinding (performance bias and detection
bias)
All outcomes
High risk Single-blind study - outcome assessors were
blinded but the majority of the measures
were based on patient self report
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data were presented for all the
children recruited in each arm
The paper reports that patients were ex-
cluded if they showed no improvement by
day 4 of the intervention Direct communi-
cation with authors revealed that no chil-
dren were excluded for this reason
Selective reporting (reporting bias) High risk Very limited reporting of outcome mea-
sures
Other bias High risk If no improvement was seen in fever nasal
congestion or cough, or if exacerbation of
diseasewas evident, patientswere reassessed
and the antibiotics were changed if neces-
sary. Following direct communication with
the authors they stated that “As a whole,
patients were assessed again and the antibi-
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Rahmati 2013 (Continued)
otics were changed if necessary at any time.
In fact, most of the patient had received a
different treatment, if they did not response
to the first line antibiotic therapy after 3
days of the initial treatment.” The type and
duration of antibiotic usage if changed is
not reported and so may have introduced
performance bias
The type and duration of antibiotics once
changed is not reported and so may have
introduced performance bias
Comparability of groups on different prog-
nostic characteristics
Low risk Symptom severity scores were 22.46 +/- 2.
61 and 23.50 +/- 3.19 before treatment,
however it is unclear how this was calcu-
lated
The authors state in the text that “clini-
cal features were almost similar at baseline
of the study...and the differences between
them are negligible” but the table they re-
fer to in support of this statement does not
offer any relevant data
In personal communication the authors
stated that there were no statistical differ-
ences in baseline prognostic characteristics
BDP: beclomethasone dipropionate
PCR: polymerase chain reaction
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Baccioglu Kavut 2013 Defined non-allergic rhinitis as those cases that were not infection
Bellodi 2006 Population was children with chronic nasal obstruction
Farr 1990 Experimentally induced rhinovirus infection. Steroid administered before inoculation
Gustafson 1996 Experimentally induced rhinovirus infection. Steroid administered before inoculation
Keith 2012 Symptoms lasted for longer than 10 days - beyond the natural history of the common cold
Lenander-Lumikari 1999 No relevant outcome measures reported. Same study population as Puhakka 1998
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(Continued)
Mygind 1977 Review article focusing on perennial and allergic rhinitis (no abstract available initially and so we obtained
full text)
Peynegre 2005 No direct comparison between steroid and placebo - groups treated otherwise unequally in terms of type
of vasoconstrictor and presence/absence of mucolytic
Proud 1994 Experimentally induced rhinovirus infection. Steroid administered before inoculation. Same patient
population as Farr et al but examining biochemical markers rather than symptoms
Reinert 1991 No direct comparison between steroid and placebo - steroid group also received intranasal neomycin
Tugrul 2014 Symptoms lasted for longer than 10 days - beyond the natural history of the common cold
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D A T A A N D A N A L Y S E S
Comparison 1. Rhinovirus infection
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of patients
with rhinovirus-positive
nasopharyngeal aspirates at day
7 of treatment
1 199 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.73, 1.34]
Analysis 1.1. Comparison 1 Rhinovirus infection, Outcome 1 Number of patients with rhinovirus-positive
nasopharyngeal aspirates at day 7 of treatment.
Review: Corticosteroids for the common cold
Comparison: 1 Rhinovirus infection
Outcome: 1 Number of patients with rhinovirus-positive nasopharyngeal aspirates at day 7 of treatment
Study or subgroup Corticosteroid Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Puhakka 1998 45/100 45/99 100.0 % 0.99 [ 0.73, 1.34 ]
Total (95% CI) 100 99 100.0 % 0.99 [ 0.73, 1.34 ]
Total events: 45 (Corticosteroid), 45 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.06 (P = 0.95)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours corticosteroid Favours placebo
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A P P E N D I C E S
Appendix 1. MEDLINE and CENTRAL search strategy
1 Common Cold/ (3092)
2 common cold*.tw. (2266)
3 coryza.tw. (333)
4 Respiratory Tract Infections/ (27457)
5 upper respiratory tract infection*.tw. (3093)
6 upper respiratory infection*.tw. (1605)
7 (uri or urti).tw. (795)
8 Epiglottitis/ (826)
9 epiglottitis.tw. (1100)
10 Rhinitis/ (7046)
11 rhinitis.tw. (15548)
12 Nasopharyngitis/ (227)
13 (rhinopharyngitis or nasopharyngitis).tw. (354)
14 Nasal Obstruction/ (2895)
15 Sneezing/ (674)
16 (rhinorrhoea or rhinorrhoea).tw. (2839)
17 ((nasal or nose*) adj2 (runny or running or congest* or blocked or discharg*)).tw. (2790)
18 Rhinovirus/ (2389)
19 rhinovir*.tw. (2747)
20 coronavirus/ or coronavirus 229e, human/ or coronavirus nl63, human/ or coronavirus oc43, human/ (1001)
21 coronavir*.tw. (5880)
22 Adenoviruses, Human/ (5968)
23 adenoviridae infections/ or adenovirus infections, human/ (5437)
24 adenovir*.tw. (35954)
25 Picornaviridae Infections/ (1023)
26 Enterovirus Infections/ (3197)
27 Coxsackievirus Infections/ (3252)
28 Echovirus Infections/ (917)
29 enterovirus/ or enterovirus a, human/ or exp enterovirus b, human/ or enterovirus c, human/ or enterovirus d, human/ (8810)
30 (pircornavir* or enterovir* or echovir* or coxsackie*).tw. (10659)
31 respiratory syncytial viruses/ or respiratory syncytial virus, human/ (5432)
32 Respiratory Syncytial Virus Infections/ (3715)
33 (respiratory syncytial virus infection* or rsv).tw. (6792)
34 parainfluenza virus 2, human/ or parainfluenza virus 4, human/ (246)
35 parainfluenza virus 1, human/ or parainfluenza virus 3, human/ (3514)
36 parainfluenza*.tw. (4196)
37 Epstein-Barr Virus Infections/ (4070)
38 (epstein-barr or epstein barr or ebv).tw. (25436)
39 Orthomyxoviridae/ (9572)
40 Orthomyxoviridae Infections/ (5322)
41 exp Influenzavirus A/ (21562)
42 exp Influenzavirus B/ (2514)
43 Influenzavirus C/ (260)
44 (influenzavirus* or influenza virus*).tw. (18748)
45 orthomyxovir*.tw. (303)
46 Paramyxoviridae Infections/ (2177)
47 paramyxovir*.tw. (2411)
48 Cytomegalovirus Infections/ (17819)
49 cytomegalovir*.tw. (28732)
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50 simplexvirus/ or herpesvirus 1, human/ (22653)
51 Herpesvirus 4, Human/ (18492)
52 or/1-51 (238889)
53 exp Glucocorticoids/ (144252)
54 glucocorticoid*.tw,nm. (70536)
55 exp Hydroxycorticosteroids/ (114224)
56 hydroxycorticosteroid*.tw,nm. (6472)
57 exp Pregnenediones/ (151889)
58 pregnenedione*.tw,nm. (1896)
59 pregnenolone*.tw,nm. (6061)
60 hydrocortisone.tw,nm. (60234)
61 hydroxypregnenolone.tw,nm. (846)
62 tetrahydrocortisol.tw,nm. (424)
63 cortodoxone.tw,nm. (746)
64 cortisone.tw,nm. (17357)
65 corticosterone.tw,nm. (25049)
66 triamcinolone.tw,nm. (8007)
67 prednisone.tw,nm. (39528)
68 prednisolone.tw,nm. (33196)
69 paramethasone.tw,nm. (218)
70 methylprednisolone.tw,nm. (18039)
71 dexamethasone.tw,nm. (50373)
72 clobetasol.tw,nm. (1031)
73 beclomethasone.tw,nm. (3165)
74 betamethasone.tw,nm. (5764)
75 budesonide.tw,nm. (3773)
76 corticosteroid*.tw,nm. (61498)
77 steroid*.tw,nm. (223268)
78 (efcortesol or hydrocortone or solu-cortef ).tw,nm. (25)
79 (betnelan or betnesol).tw,nm. (25)
80 (deflazacort or calcort).tw,nm. (389)
81 (medrone or solu-medrone or depo-medrone).tw,nm. (12)
82 kenalog.tw,nm. (148)
83 (novolizer or pulmicort or symbicort).tw,nm. (248)
84 (beclometasone or aerobec or asmabec or beclazone or becodisks or becotide or clenil modulite or qvar or becloforte).tw,nm. (221)
85 or/53-84 (530327)
86 52 and 85 (8306)
87 randomized controlled trial.pt. (299024)
88 controlled clinical trial.pt. (81706)
89 randomized.ab. (206825)
90 placebo.ab. (121696)
91 clinical trials as topic.sh. (152139)
92 randomly.ab. (150335)
93 trial.ti. (88765)
94 87 or 88 or 89 or 90 or 91 or 92 or 93 (696129)
95 exp animals/ not humans.sh. (3533521)
96 94 not 95 (643057)
97 86 and 96 (1372)
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Appendix 2. EMBASE.com search strategy
#58. #54 AND #57 3,854 25 Feb 2011
#57. #55 OR #56 912,654 25 Feb 2011
#56. random*:ab,ti OR placebo* OR factorial*:ab,ti OR crossover*:ab,ti OR ’cross over’:ab,ti OR ’cross-over’:ab,ti OR volunteer*:ab,ti
OR assign*:ab,ti OR allocat*:ab,ti OR ((singl* OR doubl*) NEAR/1 blind*):ab,ti AND [embase]/lim 881,603 25 Feb 2011
#55. ’randomized controlled trial’/exp OR ’single blind procedure’/exp OR ’double blind procedure’/exp OR ’crossover procedure’/exp
AND [embase]/lim 237,517 25 Feb 2011
#54. #41 AND #53 18,703 25 Feb 2011
#53. #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 620,492 25 Feb 2011
#52. beclometasone:ab,ti OR aerobec:ab,ti OR asmabec:ab,ti OR beclazone:ab,ti OR becodisks:ab,ti OR becotide:ab,ti OR ’clenil
modulite’:ab,ti OR qvar:ab,ti OR becloforte:ab,ti AND [embase]/lim 421 25 Feb 2011
#51. novolizer:ab,ti OR pulmicort:ab,ti OR symbicort:ab,ti AND [embase]/lim 292 25 Feb 2011
#50. kenalog:ab,ti AND [embase]/lim 117 25 Feb 2011
#49. medrone:ab,ti OR ’solu-medrone’:ab,ti OR ’depo-medrone’:ab,ti AND [embase]/lim 14 25 Feb 2011
#48. deflazacort:ab,ti OR calcort:ab,ti AND [embase]/lim 394 25 Feb 2011
#47. efcortesol:ab,ti OR hydrocortone:ab,ti OR ’solu cortef ’:ab,ti OR betnelan:ab,ti OR betnesol:ab,ti AND [embase]/lim 49 25 Feb
2011
#46. steroid*:ab,ti OR hydrocortisone:ab,ti OR hydroxypregnenolone:ab,ti OR pregnenolone:ab,ti OR tetrahydrocortisol:ab,ti OR
cortodoxone:ab,ti OR cortisone:ab,ti OR corticosterone:ab,ti OR
triamcinolone:ab,ti OR prednisone:ab,ti OR prednisolone:ab,ti OR paramethasone:ab,ti OR methylprednisolone:ab,ti OR dexam-
ethasone:ab,ti OR clobetasol:ab,ti OR beclomethasone:ab,ti OR
beclometasone:ab,ti OR betamethasone:ab,ti OR budesonide:ab,ti AND [embase]/lim 255,337 25 Feb 2011
#45. ’cortodoxone’/de AND [embase]/lim 1,260 25 Feb 2011
#44. ’pregnane derivative’/de AND [embase]/lim 528 25 Feb 2011
#43. corticosteroid*:ab,ti OR glucocorticoid*:ab,ti OR hydrocorticosteroid*:ab,ti OR hyroxcorticosteroid*:ab,ti AND [embase]/lim
105,815 25 Feb 2011
#42. ’corticosteroid’/exp AND [embase]/lim 495,099 25 Feb 2011
#41. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31
OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 164,080 25 Feb 2011
#40. ’herpes simplex virus 1’/de AND [embase]/lim 12,865 25 Feb 2011
#39. ’simplexvirus’/de AND [embase]/lim 3 25 Feb 2011
#38. cytomegalovir*:ab,ti AND [embase]/lim 27,461 25 Feb 2011
#37. ’cytomegalovirus infection’/de AND [embase]/lim 16,718 25 Feb 2011
#36. paramyxovir*:ab,ti AND [embase]/lim 1,988 25 Feb 2011
#35. ’paramyxovirus infection’/de AND [embase]/lim 9 25 Feb 2011
#34. influenzavir*:ab,ti OR ’influenza virus’:ab,ti OR ’influenza viruses’:ab,ti AND [embase]/lim 9 25 Feb 2011
#33. ’influenza virus a’/exp OR ’influenza virus b’/de OR ’influenza virus c’/de AND [embase]/lim 15,442 25 Feb 2011
#32. orthomyxovir*:ab,ti AND [embase]/lim 249 25 Feb 2011
#31. ’orthomyxovirus infection’/de OR ’orthomyxovirus’/de AND [embase]/lim 638 25 Feb 2011
#30. ’epstein barr’:ab,ti OR ’epstein-barr’:ab,ti OR ebv:ab,ti AND [embase]/lim 24,877 25 Feb 2011
#29. ’epstein barr virus infection’/de AND [embase]/lim 522 25 Feb 2011
#28. parainfluenza*:ab,ti AND [embase]/lim 3,453 25 Feb 2011
#27. ’parainfluenza virus’/exp AND [embase]/lim 4,200 25 Feb 2011
#26. ’respiratory syncytial virus’:ab,ti OR ’respiratory syncytial viruses’:ab,ti OR rsv:ab,ti AND [embase]/lim 9,130 25 Feb 2011
#25. ’respiratory syncytial pneumovirus’/de OR ’respiratory syncytial virus infection’/de AND [embase]/lim 8,874 25 Feb 2011
#24. picornavir*:ab,ti OR enterovir*:ab,ti OR echovir*:ab,ti OR coxsackie*:ab,ti AND [embase]/lim AND [2007-2011]/py 2,146 25
Feb 2011
#23. ’picornavirus infection’/de OR ’enterovirus infection’/de OR ’coxsackie virus infection’/de OR ’echovirus infection’/de AND
[embase]/lim AND [2007-2011]/py 538 25 Feb 2011
#22. adenovir*:ab,ti AND [embase]/lim AND 8,654 25 Feb 2011 [2007-2011]/py
#21. ’human adenovirus infection’/de AND [embase]/lim AND [2007-2011]/py 19 25 Feb 2011
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#20. ’human adenovirus’/exp AND [embase]/lim AND [2007-2011]/py 290 25 Feb 2011
#19. coronavir*:ab,ti AND [embase]/lim AND [2007-2011]/py 1,238 24 Feb 2011
#18. ’coronavirus’/de OR ’sars coronavirus’/de AND [embase]/lim AND [2007-2011]/py 1,515 24 Feb 2011
#17. rhinovir*:ab,ti AND [embase]/lim AND [2007-2011]/py 787 24 Feb 2011
#16. ’rhinovirus infection’/de OR ’human rhinovirus’/de AND [embase]/lim AND [2007-2011]/py 389 24 Feb 2011
#15. sneez*:ab,ti OR rhinorrhea:ab,ti OR rhinorrhoea:ab,ti AND [embase]/lim AND [2007-2011]/py 1,167 24 Feb 2011
#14. ’rhinorrhea’/de AND [embase]/lim AND [2007-2011]/py 1,615 24 Feb 2011
#13. ’sneezing’/de AND [embase]/lim AND [2007-2011]/py 999 24 Feb 2011
#12. ((nasal OR nose*) NEAR/2 (runny OR running OR congest* OR blocked OR discharg*)):ab,ti AND [2007-2011]/py 1,001 24
Feb 2011
#11. ’nose obstruction’/de AND [embase]/lim 4,571 24 Feb 2011
#10. rhinitis:ab,ti OR nasopharyngitis:ab,ti OR rhinopharyngitis:ab,ti AND [embase]/lim 17,156 24 Feb 2011
#9. ’rhinitis’/de OR ’rhinopharyngitis’/de OR ’nose infection’/de AND [embase]/lim 13,616 24 Feb 2011
#8. epiglottitis:ab,ti AND [embase]/lim 944 24 Feb 2011
#7. ’epiglottitis’/exp AND [embase]/lim 1,349 24 Feb 2011
#6. uri:ab,ti OR urti:ab,ti AND [embase]/lim 879 24 Feb 2011
#5. ’upper respiratory tract infection’:ab,ti OR ’upper respiratory tract infections’:ab,ti OR ’upper respiratory infection’:ab,ti OR ’upper
respiratory infections’:ab,ti AND [embase]/lim 4,873 24 Feb 2011
#4. ’upper respiratory tract infection’/de AND [embase]/lim 10,775 24 Feb 2011
#3. coryza:ab,ti AND [embase]/lim 196 24 Feb 2011
#2. ’common cold’:ab,ti OR ’common colds’:ab,ti AND [embase]/lim 2,062 24 Feb 2011
#1. ’common cold’/de AND [embase]/lim 3,684 24 Feb 2011
F E E D B A C K
Corticosteroids for the common cold, 2 November 2015
Summary
Comment: I am a layman but I’ve noted that steroid inhalers usually take 8 weeks, 2 weeks orally. If this is correct results are unsurprising.
How about a trial of steroids for those who get regular colds - either those in large population exposure or, perhaps more likely
beneficiaries, the vulnerable to infections. Or even mass-population trialling, assuming limited side effects of continual use.
Paul Harris
I agree with the conflict of interest statement below:
I certify that I have no affiliations with or involvement in any organization or entity with a financial interest in the subject matter of
my feedback.
Reply
Our systematic review asked whether steroids could improve symptoms of the common cold, and did not address the question of
whether regular steroid use could prevent the common cold. However, we excluded two trials where the participants were given oral or
intra-nasal steroids before being experimentally infected with a virus known to cause colds and we describe the findings of these trials
in our discussion section. Both of these trials had small numbers of participants and they offered inconsistent evidence of a benefit of
preventative steroid therapy. Therefore, a larger trial is needed to understand whether this approach might be beneficial, but there are
health risks associated with long term steroid use, particularly oral steroid use, which might well make this approach unpopular even
if it were shown to be effective.
Contributors
Gail Hayward
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WH A T ’ S N E W
Last assessed as up-to-date: 19 May 2015.
Date Event Description
11 March 2016 Feedback has been incorporated Feedback comment and reply added to the review.
H I S T O R Y
Protocol first published: Issue 4, 2009
Review first published: Issue 8, 2012
Date Event Description
19 May 2015 New search has been performed Searches updated. We included one new trial (Rahmati
2013), and excluded three new trials (Baccioglu Kavut
2013; Keith 2012; Tugrul 2014).
19 May 2015 New citation required but conclusions have not
changed
The addition of one further trial does not change the
conclusions of the review
6 September 2012 Amended Acknowledgements section amended.
16 June 2010 Amended Contact details updated.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Wehave added an additional exclusion criterion as follows: “We also excluded trials where the common cold was experimentally induced
if the intervention was initiated before the cold was induced.” We made this decision once the range of eligible papers was established
as we had not anticipated trials using experimentally induced infections.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Intranasal; Adrenal Cortex Hormones [∗therapeutic use]; Androstadienes [∗therapeutic use]; Beclomethasone
[∗therapeutic use]; Common Cold [∗drug therapy]; Fluticasone [therapeutic use]; Randomized Controlled Trials as Topic; Treatment
Outcome
MeSH check words
Adolescent; Adult; Child; Child, Preschool; Female; Humans; Male
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